For example, in individuals with obesity and type 2 diabetes, FGF21 analogs attenuate dyslipidemia but have less impact on glycemic control, which demonstrates the differences that still exist among different FGF21 analogs and the differences in action between species (72). The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.